Principal Financial Group
NWBO

Principal Financial Group’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Principal Financial Group’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-12,868
Closed -$128K – 2297
2015
Q2 		$128K Buy
+12,868
New +$113K ﹤0.01% 2109
2014
Q4 		– Sell
-11,638
Closed -$59K – 2308
2014
Q3 		$59K Hold
11,638
– – ﹤0.01% 2177
2014
Q2 		$78K Buy
+11,638
New +$74.1K ﹤0.01% 2215

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Principal Financial Group's NWBO Position: Q3 2015 in Review

Principal Financial Group sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2015, closing a stake of 12,868 shares — an estimated $128K sold.

Principal Financial Group first reported a position in NWBO in Q2 2014 and held it in 3 quarters. The position peaked at $128K in Q2 2015. 79 funds tracked by Wall St. Rank hold NWBO as of Q3 2015.

  • Principal Financial Group reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2015 after selling out during the quarter.
  • Principal Financial Group sold 12,868 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2015, an estimated $128K.
  • Principal Financial Group first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2014 and held it in 3 quarters.
  • Principal Financial Group's Northwest Biotherapeutics, Inc. Common stock position peaked at $128K in Q2 2015.
  • 79 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2015.

Based on Principal Financial Group's 13F filing for Q3 2015, filed 9 Nov 2015.